Pro Medicus Limited (ASX:PME): What Do FY26 Earnings and New Imaging Contracts Reveal?

Aditi Sarkar

27 October 2026 10:29 PM AEDT

Pro Medicus Limited (ASX:PME): What Do FY26 Earnings and New Imaging Contracts Reveal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus Limited (ASX:PME) reported FY26 revenue of AUD 261.7mn, up 22.9% YoY.
Underlying EBIT increased 24.4% YoY to AUD 196.1mn, with a 74.9% margin.
Ten new contracts carried a combined minimum value of AUD 407mn during FY26.
Underlying NPAT rose 24.1% YoY to AUD 144.7mn; the company remained debt-free.

Pro Medicus Limited develops medical imaging software used by hospitals, imaging centres and health systems. Following its FY26 results and announcements concerning new imaging contracts, Pro Medicus Limited (ASX:PME) shares closed at AUD 198.41 on 27 October 2026. The annual figures show growth in operating earnings and contracted work, while the difference between statutory and underlying profit warrants attention because investment revaluations materially affected reported earnings.

Company Business

Pro Medicus Limited (ASX:PME) supplies imaging informatics software and associated services, primarily through its Visage Imaging business. The Visage 7 platform supports radiology image viewing, image archiving and workflow functions.

The company serves healthcare organisations internationally, with operations in Australia, the United States and Germany. A material part of its commercial model involves longer-term software agreements, implementation work and revenue generated as customers use deployed systems.

Recent Development

In August 2026, Pro Medicus Limited (ASX:PME) reported ten new contracts signed during FY26 with a combined minimum value of AUD 407mn. It also renewed all six contracts due for renewal in the period, representing AUD 141mn over five-year terms. Management reported sixteen implementations during the year, reflecting the work required to convert contracted projects into operational systems.

The company identified a ten-year AUD 170mn agreement with UC Health Colorado and a seven-year AUD 90mn agreement with Beth Israel Lahey Health among its new business. It also reported that its Trinity implementation was largely complete and positioned to contribute for the full FY27 financial year. Product additions during FY26 included digital pathology and AI-optimised reporting, extending the software applications addressed by the group.

Separately, an August 2026 announcement identified a seven-year AUD 25mn contract with Valley Health.

Financial Performance and Sector Context

For the year ended 30 June 2026, Pro Medicus Limited (ASX:PME) reported revenue of AUD 261.7mn, compared with AUD 213.0mn in FY25, an increase of 22.9% YoY. Underlying EBIT rose 24.4% to AUD 196.1mn, and the underlying EBIT margin reached 74.9%, an improvement of 90 basis points. On a constant-currency basis, revenue was AUD 273.5mn, representing growth of 28.4% YoY.

Underlying net profit after tax increased 24.1% YoY to AUD 144.7mn. Statutory NPAT was substantially higher at AUD 265.3mn, up 130.3% YoY. The distinction is important: statutory earnings included significant unrealised fair-value investment gains, which should not be treated as recurring software operating earnings.

Net operating cash inflow for FY26 was AUD 127.5mn. At 30 June 2026, cash and other financial assets totalled AUD 252.3mn, up 19.7%, and the company reported no debt. Its fully franked final dividend was 37 Australian cents per share, bringing the full-year dividend to 69 cents, up 25.5%. Foreign-exchange movements remain relevant because a substantial portion of business activity occurs outside Australia.

Healthcare providers' demand for imaging systems reflects workflow efficiency, digital infrastructure investment and requirements for clinical image access. However, hospital procurement processes, security obligations and system integration can make sales and implementations lengthy. The company's contracted pipeline therefore needs to be considered alongside the pace of customer deployments and actual usage.

Risks to Consider

Pro Medicus Limited (ASX:PME) is exposed to implementation delays, customer technology budgets, cybersecurity requirements and competition in imaging software. Large hospital contracts can create concentration and uneven project timing. Revenue translated from overseas currencies is sensitive to exchange rates. Changes in the valuation of financial investments can also cause statutory profit to diverge markedly from underlying operating performance.

What to Watch Next

Investors following Pro Medicus Limited (ASX:PME) can monitor the conversion of newly announced contracts into installations and recurring revenue during FY27. Relevant developments include the full-period contribution of the Trinity rollout, the implementation of other customer agreements and the adoption of digital pathology and reporting products.

Key Insights

Pro Medicus Limited (ASX:PME) recorded higher FY26 revenue and underlying earnings, signed new imaging contracts and ended the year debt-free. Reported statutory profit benefited substantially from investment fair-value movements, making underlying results useful for assessing the software business. Contract implementation, customer usage, currency translation and the development of newer imaging products are the principal operational measures to follow in FY27.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.